Cell reports :SMAD4缺失促进肺癌生长转移新发现

2015-03-18 佚名 不详

近日,国际期刊cell reports发表了美国科学家的一项最新研究进展,他们发现ERBB2/AKT/ELF3信号途径在肺癌发生发展过程中具有重要作用。   目前,肺癌仍是对人类生命健康威胁最大的恶性肿瘤之一。肺癌的发生和发展主要是由PTEN,p53和SMAD4等肿瘤抑制性基因的失活性突变以及Kras,EGFR和ERBB2等调控细胞增殖的癌基因的激活性突变逐步积累导致的。之前研究发现

近日,国际期刊cell reports发表了美国科学家的一项最新研究进展,他们发现ERBB2/AKT/ELF3信号途径在肺癌发生发展过程中具有重要作用。
 
目前,肺癌仍是对人类生命健康威胁最大的恶性肿瘤之一。肺癌的发生和发展主要是由PTEN,p53和SMAD4等肿瘤抑制性基因的失活性突变以及Kras,EGFR和ERBB2等调控细胞增殖的癌基因的激活性突变逐步积累导致的。之前研究发现,小鼠肺部基底层细胞中Pten缺失会诱发肺部肿瘤形成,但发生率极低且需要长时间等待。
 
在该项研究中,研究人员通过对鳞状细胞癌病人的肺部肿瘤进行基因组测序发现SMAD4突变率较高。因此研究人员利用Pten和SMAD4缺失小鼠模型研究SMAD4缺失导致肺癌进一步发展的分子机制。结果发现肺上皮细胞缺失Pten和Smad4会导致小鼠发生转移性腺鳞癌。通过对转录组比较分析和体内顺反组分析发现PTEN和SMAD4缺失会下调ERRFI1表达,而ERRFI1是小鼠和人类细胞中ERBB2的负调控因子,因此导致ELF4和ERBB2通路激活。研究人员进一步发现抑制ERBB2和AKT信号通路能够延缓肿瘤进展和细胞侵袭。
 
通过对人类肺癌进行表达谱分析,研究人员证实了ERBB2/AKT/ELF3信号途径在肺癌发生发展过程中的重要性,对于肺癌的诊断和治疗药物开发具有重要意义。

原文出处:

Jian Liu8, Sung-Nam Cho8, Bindu Akkanti, Nili Jin, Jianqiang Mao, Weiwen Long, Tenghui Chen, Yiqun Zhang, Ximing Tang, Ignacio I. Wistub, Chad J. Creighton, Farrah Kheradmand, Francesco J. DeMayo.ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis.Cell Reports.Volume 10, Issue 9, p1599–1613, 10 March 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1921110, encodeId=7bdb1921110ef, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Aug 09 12:55:00 CST 2015, time=2015-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794127, encodeId=fe021e9412765, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Tue May 12 02:55:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959294, encodeId=2f3d1959294e9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 05 06:55:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869043, encodeId=88e6186904340, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 27 16:55:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388825, encodeId=5565138882532, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri Mar 20 02:55:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18499, encodeId=577a18499f2, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Thu Mar 19 08:41:00 CST 2015, time=2015-03-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1921110, encodeId=7bdb1921110ef, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Aug 09 12:55:00 CST 2015, time=2015-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794127, encodeId=fe021e9412765, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Tue May 12 02:55:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959294, encodeId=2f3d1959294e9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 05 06:55:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869043, encodeId=88e6186904340, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 27 16:55:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388825, encodeId=5565138882532, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri Mar 20 02:55:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18499, encodeId=577a18499f2, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Thu Mar 19 08:41:00 CST 2015, time=2015-03-19, status=1, ipAttribution=)]
    2015-05-12 wshxjq
  3. [GetPortalCommentsPageByObjectIdResponse(id=1921110, encodeId=7bdb1921110ef, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Aug 09 12:55:00 CST 2015, time=2015-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794127, encodeId=fe021e9412765, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Tue May 12 02:55:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959294, encodeId=2f3d1959294e9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 05 06:55:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869043, encodeId=88e6186904340, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 27 16:55:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388825, encodeId=5565138882532, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri Mar 20 02:55:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18499, encodeId=577a18499f2, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Thu Mar 19 08:41:00 CST 2015, time=2015-03-19, status=1, ipAttribution=)]
    2015-12-05 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1921110, encodeId=7bdb1921110ef, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Aug 09 12:55:00 CST 2015, time=2015-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794127, encodeId=fe021e9412765, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Tue May 12 02:55:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959294, encodeId=2f3d1959294e9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 05 06:55:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869043, encodeId=88e6186904340, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 27 16:55:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388825, encodeId=5565138882532, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri Mar 20 02:55:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18499, encodeId=577a18499f2, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Thu Mar 19 08:41:00 CST 2015, time=2015-03-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1921110, encodeId=7bdb1921110ef, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Aug 09 12:55:00 CST 2015, time=2015-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794127, encodeId=fe021e9412765, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Tue May 12 02:55:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959294, encodeId=2f3d1959294e9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 05 06:55:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869043, encodeId=88e6186904340, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 27 16:55:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388825, encodeId=5565138882532, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri Mar 20 02:55:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18499, encodeId=577a18499f2, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Thu Mar 19 08:41:00 CST 2015, time=2015-03-19, status=1, ipAttribution=)]
    2015-03-20 江川靖瑶
  6. [GetPortalCommentsPageByObjectIdResponse(id=1921110, encodeId=7bdb1921110ef, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Aug 09 12:55:00 CST 2015, time=2015-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794127, encodeId=fe021e9412765, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Tue May 12 02:55:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959294, encodeId=2f3d1959294e9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 05 06:55:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869043, encodeId=88e6186904340, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 27 16:55:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388825, encodeId=5565138882532, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri Mar 20 02:55:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18499, encodeId=577a18499f2, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Thu Mar 19 08:41:00 CST 2015, time=2015-03-19, status=1, ipAttribution=)]
    2015-03-19 drhqh240

    的确不错

    0

相关资讯

原发性肺癌放射治疗的规范解读

国家卫生和计划生育委员会(原卫生部)发布2011版《原发性肺癌诊疗规范》(以下简称《规范》)后,今年国家卫生和计划生育委员会组织专家首次对其进行修订,目前已发布2015版《规范》。在新版的诊疗规范中,放射治疗方面有哪些增改内容?我们特邀山东省肿瘤医院于金明院士作了详尽解读。再次强调多学科综合治疗与个体化治疗相结合的原则2015版《规范》中再次强调要综合分析患者病情,采取多学科综合治疗与个体化治

《原发性肺癌诊疗规范》更新内容(2015)

近几年,世界范围内原发性肺癌的内科治疗又有了迅猛的发展。更多肺癌驱动基因被发现和了解,使得肺癌患者在治疗前不仅要明确组织病理类型,还要明确分子病理类型。ALK融合基因及相应靶向治疗药物克唑替尼这片“新大陆”的发现,使我们对EGFR分子靶向治疗的理解又加深了一个层次。培美曲塞对于非鳞癌患者的疗效给大部分非小细胞肺癌(NSCLC">NSCLC)患者带来好消息,在分子靶向治疗时代,化疗的地位依

ACS Nano:医疗纳米粒子:肺癌的局部治疗

纳米粒子可以作为对抗肺癌药物的载体。NIM(纳米系统倡议者慕尼黑)卓越集群的联合项目,来自亥姆霍兹慕尼黑中心(HMGU)和路德维希 - 马克西米利安大学(LMU)在慕尼黑的科学家已经开发了一种纳米粒子可作为载体的药物,人类和小鼠的肺部肿瘤部位有选择地释放药物。在 “ACS Nano” 杂志中,科学家报告说,这种做法使目前的抗癌药物在肺癌肿瘤组织的有效性显著增加。 纳米颗粒是极其微小的粒子,可将其

靶向为翼,肺癌患者生存期十年飞速提升2.4倍

3月14日,由抗癌协会临床肿瘤学协作专业委员会主办、阿斯利康中国协办的"下一个十年,下一个飞跃"中国非小细胞肺癌靶向治疗10年高端峰会在沪召开。回顾了伴随着靶向治疗药物与技术进入中国、肺癌治疗突飞猛进的十年历程;并在此基础上,探讨了EGFR基因检测与个体化治疗的最新进展;并对各方携手、共促非小细胞肺癌治疗未来发展献计献策。中国抗癌协会临床肿瘤学协作专业委员会(CSCO)主任委员、中国抗癌协会(CA

肺部鳞癌常见基因改变—PIK3CA扩增和突变

PIK3CA编码p110-α蛋白,该蛋白为磷脂酰肌醇3激酶(PI3K)的催化亚单位。PI3K通路与许多调节细胞重要功能的信号相关,如细胞生长、增殖、分化、运动和存活。在P110-α蛋白中氨基酸R38、R93、K111、E453、E545、Q546、M1043和H1047上发现PIK3CA错义突变,且该种突变有致瘤性。TCGA数据库中10%的肺鳞状细胞癌和7%的肺腺癌均出现PIK3CA的突变。研究表